key: cord-1055872-eai75opk
authors: Chen, Da-Yuan; Khan, Nazimuddin; Close, Brianna J.; Goel, Raghuveera K.; Blum, Benjamin; Tavares, Alexander H.; Kenney, Devin; Conway, Hasahn L.; Ewoldt, Jourdan K.; Kapell, Sebastian; Chitalia, Vipul C.; Crossland, Nicholas A.; Chen, Christopher S.; Kotton, Darrell N.; Baker, Susan C.; Connor, John H.; Douam, Florian; Emili, Andrew; Saeed, Mohsan
title: SARS-CoV-2 desensitizes host cells to interferon through inhibition of the JAK-STAT pathway
date: 2020-10-28
journal: bioRxiv
DOI: 10.1101/2020.10.27.358259
sha: 1749b9fac198e60beb2492bb2332b6a008a01e67
doc_id: 1055872
cord_uid: eai75opk

SARS-CoV-2 can infect multiple organs, including lung, intestine, kidney, heart, liver, and brain. The molecular details of how the virus navigates through diverse cellular environments and establishes replication are poorly defined. Here, we performed global proteomic analysis of the virus-host interface in a newly established panel of phenotypically diverse, SARS-CoV-2-infectable human cell lines representing different body organs. This revealed universal inhibition of interferon signaling across cell types following SARS-CoV-2 infection. We performed systematic analyses of the JAK-STAT pathway in a broad range of cellular systems, including immortalized cell lines and primary-like cardiomyocytes, and found that several pathway components were targeted by SARS-CoV-2 leading to cellular desensitization to interferon. These findings indicate that the suppression of interferon signaling is a mechanism widely used by SARS-CoV-2 in diverse tissues to evade antiviral innate immunity, and that targeting the viral mediators of immune evasion may help block virus replication in patients with COVID-19.

complication of disambiguating a mixture of uninfected and infected cells. The ACE2/TMPRSS2expressing A549 (lung), Caco-2 (intestine), HuH-6 (liver), AC-16 (heart), SK-N-SH (brain), and HK-2 (kidney) cells were infected with SARS-CoV-2 at an MOI of 1 and subjected to global proteomic analysis at two different times post-infection (12 and 24 hpi for A549, Caco-2, and HuH-6; 8 and 12 hpi for AC-16, SK-N-SH, and HK-2) (Fig. 3a) . To achieve a synchronized infection, we adsorbed the virus onto cells on ice for 1h followed by incubation at 37ºC. The infections were performed in triplicate, and in-parallel analyses of time-matched, mock-infected cells were performed for comparison. Depending on the cell type, 50-80% cells were found infected at the first time of harvest and 80-100% at the second time (Fig. 3b, 

Whole proteomic analysis identified around 5,000 proteins in both uninfected and infected cells across cell lines. Despite the fact that MS 2 -based TMT ratios are heavily affected by ratio compression 15 , the high reproducibility among replicates allowed us to identify hundreds of differentially regulated proteins in each cell line (Fig. 3b, middle and bottom panels) . As expected, the most highly enriched candidates in the infected cells were the viral proteins ( Fig.   3c and Extended Data Fig. 3) , including structural proteins, such as, spike (S), membrane (M), and nucleocapsid (N); accessory proteins, such as, ORF7a and ORF9b; and non-structural components mapping to the polyprotein PP1ab (Fig. 3d) , which is consistent with earlier studies 16 .

Several cellular proteins were found to be differentially affected by SARS-CoV-2 in diverse or distinct cell types ( Supplementary Information and Extended Data Fig. 4) . We mainly focused our analysis on proteins broadly targeted by the virus across cell lines (Fig. 3e) . Among such proteins were the members of the ubiquitin pathway, such as USP22, UBL5, and UBE2C, which were downregulated in several cell lines. Similarly, HNRNPD (aka AUF1), a protein known to inhibit enteroviruses through degradation of the viral RNA 17 , was depleted in SARS-CoV-2infected cells. Several chemokines, which are essential mediators of inflammation and play important roles in controlling viral infections, such as CXCL1, CXCL5, CXCL8, and CXCL12 were also among the downregulated proteins. Consistent with previous reports, several proteins involved in the cell cycle regulation, including AURKA and AURKB, were diminished upon SARS-CoV-2 infection 18 . We also identified differential regulation of several innate immune components in the proteomic dataset. For instance, JAK1 and SERPINE1 were downregulated, whereas IFI35, which has been shown to negatively regulate antiviral responses, was enriched following SARS-CoV-2 infection (Fig. 3e) .

We performed Western blot analysis on a subset of proteins that showed differential regulation in our proteomics analysis. As controls, we included two additional viruses, yellow fever virus (YFV) and Coxsackievirus B3 (CVB3), to rule out any general stress responses induced upon a positive-sense RNA virus infection (Fig. 4a) . Western blotting largely revealed the protein expression patterns consistent with the proteomics results (Fig. 4b) . As an example, USP22 was depleted in all cell lines tested, while APOE was impaired in a small subset of cells. For the most part, YFV and CVB3 infection did not affect the selected proteins, with the exception of TOB2, that was depleted in all virus-infected cells. These results confirmed the authenticity of our proteomic dataset and indicate that most of the alterations we detected in the infected cells were specifically due to SARS-CoV-2 infection rather than simply a generic response to viral invasion.

Among the cellular proteins downregulated across all cell lines was Janus kinase 1 (JAK1) (Fig. 4b) , a key signaling molecule downstream of interferons (IFN) and other cytokines, such as interleukin (IL)-2, IL-4, IL-6, and IL-7 19, 20 . This prompted us to examine other components of the IFN signaling pathway. Tyrosine kinase 2 (TYK2) showed decreased expression similar to JAK1 and was downregulated in most of the cell lines tested (Fig. 5a) . Janus kinase 2 (JAK2) exhibited cell type-dependent inhibition; it was diminished in A549, Caco-2, and HuH-6 cells, but not in AC- 16 and SK-N-SH cells. When we tested the abundance of type I IFN receptors, we found strong inhibition of IFNAR1, but not IFNAR2, following SARS-CoV-2 infection (Fig. 5a) . To confirm the authenticity of these findings in a more physiologically relevant setting, we established a human induced pluripotent cell (hiPSC)-derived model of SARS-CoV-2 infection and monitored the ability of the virus to impair IFN-related proteins. We differentiated hiPSC into cardiomyocytes (hiPSC-CM) and first assessed their ability to support virus infection. IF analysis showed that these cells were highly permissive to SARS-CoV-2 infection, and when infected at an MOI of 5, most of the cells became positive by 72 hpi (Fig. 5c, left panel) . In these infected cardiomyocytes, we observed strong depletion of JAK1, TYK2, and IFNAR1, but not of IFNAR2, consistent with the cell line data (Fig. 5c, right panel) . These results clearly indicate that SARS-CoV-2 causes bona-fide inhibition of upstream signaling molecules in the interferon response pathway.

Engagement of IFN to its receptor complex and the subsequent activation of receptorassociated JAK kinases leads to tyrosine phosphorylation, dimerization, and activation of STAT proteins 21 . Because SARS-CoV-2 inhibited the expression of IFN receptor and its associated JAKs, we next determined if this inhibition desensitized the infected cells to IFN treatment. For this, we treated uninfected and infected cells with IFN-α and examined the phosphorylation of three main STATs involved in IFN signaling, namely STAT1, 2, and 3. As expected, IFN treatment of uninfected cells for 30 minutes caused extensive phosphorylation of all three STATs without influencing the abundance of total proteins ( Fig. 5d and Extended Data Fig. 5b) . In contrast, however, the virus-infected cells were highly resistant to IFN, with some cell types showing no change in STAT phosphorylation while others registering only subtle effects. The strongest effect was seen in Caco-2 cells, where STAT phosphorylation was inhibited by over 90% following virus infection (Fig. 5d, right panel) . Interestingly, the abundance of total STAT2 protein was also diminished in infected cells, indicating an additional layer of virus-imposed inhibition of IFN signaling (Fig. 5d) . To further confirm these findings, we performed a dose-response analysis of STAT phosphorylation upon IFN treatment. While escalating doses of IFN caused increasing phosphorylation of STATs in uninfected cells, only negligible effect was seen in SARS-CoV-2infected cells (Fig. 5e) .

Once activated by phosphorylation, STAT proteins make homo-or heterodimers and translocate to the nucleus where they activate the expression of interferon stimulated genes (ISGs) 21 . Consistent with the decreased phosphorylation of STAT proteins following SARS-CoV-2 infection, we observed strong inhibition of STAT1 nuclear translocation. While most of the STAT1 protein in uninfected cells moved to the nucleus within 30 min of IFN treatment, it largely remained in the cytoplasm in SARS-CoV-2-infected cells (Fig. 5f) . This was associated with a significant loss of ISG induction. We treated uninfected and virus-infected cells with IFN for 1, 2, 4, and 8h and examined the expression of two ISGs, ISG15 and RSAD2 (a.k.a. Viperin) by RT-qPCR. Remarkably, the expression of both ISGs was completely blocked in the infected cells as compared to their uninfected counterparts that showed between 3-and 85-fold upregulation of ISGs following IFN treatment ( Fig. 5g and Extended Data Fig. 6 ). In line with these findings, chemical inhibition of the JAK-STAT pathway with JAK inhibitors, Ruxolitinib and Barcitinib, increased SARS-CoV-2 infection of hiPSC-CMs, as evidenced by 1.5-to 2-fold increase in the percentage of virus-infected cells at 12 hpi, although this replicative advantage was lost by 24 hpi (Fig. 5h) . In all, these results indicate that SARS-CoV-2 targets multiple components of the JAK-STAT axis and transforms infected cells into an interferon non-responsive state (Fig. 6) .

We report an immune evasion strategy that SARS-CoV-2 uses to antagonize IFN signaling and establish infection in diverse tissue types. Being amongst the earliest and most potent of the immune responses, IFN signaling poses an immediate threat to viruses and can quickly eliminate them from the infected cells. Two recent reports have shown that inborn errors in IFN signaling and the presence of anti-IFN auto-antibodies can predispose individuals to a life-threatening COVID-19 disease, highlighting the importance of IFN immunity in SARS-CoV-2 infection 22,23 . Our findings complement these reports and show that SARS-CoV-2 has evolved a suite of mechanisms to counteract the effector functions of interferon. This inhibition of IFN signaling is also expected to attenuate the production of IFN, as these two processes are tightly regulated by a positive feedback loop, with early IFNs inducing the expression of viral sensors 24 , interferon regulatory factor 7 (IRF7), and other signaling molecules 25 , which regulate the expression of IFN 26 . The overall outcome of this inhibition is an attenuated antiviral state supporting uninterrupted viral propagation in disparate tissues.

Several studies are currently evaluating the clinical efficacy of IFN alone or in combination with antiviral compounds for the treatment of COVID-19 (https://clinicaltrials.gov). This is based on the supposition that IFNs can help clear infection in two ways. First, by acting on infected cells and eliminating the replicating virus. Second, by creating an antiviral state in uninfected cells to block viral spread. There is support for the latter mechanism of action from recent studies showing that pre-treatment with IFN can effectively inhibit SARS-CoV-2 replication in cell culture 27,28 .

However, our results show that once the viral replication is established inside a cell, its ability to respond to IFN is severely compromised, suggesting that the former potential protective mechanism of IFN treatment may not function in COVID-19 patients. In a clinical setting, by the time a patient receives IFN treatment, a large number of cells are infected with the virus, and these would be expected to be non-responsive to interferon treatment.

Considering this scenario, the timing of IFN therapy relative to infection is expected to be the key determinant of outcome. In a recent retrospective study of 446 patients with COVID-19, early use of IFN was found to be protective, whereas its late administration was associated with delayed recovery and increased mortality 29 . Similarly, the World Health Organization's largescale, multi-country clinical trial showed no protective effect of IFN in hospitalized COVID-19 patients with late-stage disease (https://www.medrxiv.org/content/10.1101/2020.10.15.20209817 v1). The same has been previously reported in mice infected with a related human coronavirus, MERS-CoV, where early administration of IFN protected the animals from lethal infection, whereas delayed administration of IFN failed to inhibit virus replication 30 .

Of note, the activation of the JAK-STAT pathway has been shown to stimulate the production of IL-6 and other inflammatory cytokines 31 , which in turn attract an army of immune cells to the site of infection to orchestrate the destruction of infected cells. Inhibition of the JAK-STAT axis by SARS-CoV-2 can therefore suppress the production of cytokines, thereby disrupting a potent and timely inflammatory response. The interferon pathway is also implicated in a crosstalk between innate and adaptive immunity 32 . Loss of bridging between these two immunity arms and the resulting timing mismatch has been postulated to cause severe disease in COVID-19 patients 33, 34 . A recent study that examined peripheral blood from patients with COVID-19 of varying severity also reported a strong correlation between impairment of IFN responses and the clinical outcome of infection 35 . These two observations, when combined, firmly point to the possibility of aberrant IFN responses to be at the heart of COVID-19 pathogenesis.

Our study reports a suite of human cell lines suitable for SARS-CoV-2 studies. Exogenous expression of ACE2 has been demonstrated to improve the susceptibility of a few human cell lines, such as A549 and HeLa, to SARS-CoV-2 36,37 , but our results show that efficient infection can only be achieved when ACE2 and TMPRSS2 are co-expressed. This finding is important because it provides a conceptual framework for generating efficient infection models for SARS-CoV-2. Human ACE2-expressing mice that are currently used to investigate SARS-CoV-2 38 do not recapitulate the full spectrum of the human disease (reviewed in 39 ). From our results, it is tempting to speculate that co-expression of human ACE2 and TMPRSS2 might improve the quality and physiological relevance of these mouse models.

The human cell lines we generated represent a rich resource that can be used to investigate cellular pathways broadly targeted by SARS-CoV-2 in diverse tissue types. While immortalized and cancerous cell lines often incompletely recapitulate the genotypic and phenotypic profile of their tissues of origin, many cell lines maintain an important degree of tissue identity 40 . This is reflected in our proteomic dataset. As an example, APOE, a protein regulated upon virus infection and which we validated by Western blot, was only found to be altered in liver and intestinal cell lines, two tissue types known to express this protein to high levels 41 . The results obtained from hiPSC-CMs closely matched with those from the cardiac cell line AC-16, providing further validity to our cell line approach (Fig. 5a, c) .

Recent studies have reported proteomic profiling of SARS-CoV-2 infection in Caco-2 16 and A549 cells (https://www.biorxiv.org/content/10.1101/2020.06.17.156455v1). These studies, however, employed relatively suboptimal infection models, and thus relied on a mosaic of infected and uninfected cells. We found little overlap between our results and those reported by others. This could be due to the differences in viral isolates, proteomic platforms, and analyses pipelines, but is likely to also be due to disparities in the number of infected cells in the cell population. Our infection models supported quick, uniform virus infection allowing us to identify SARS-CoV-2specific changes as opposed to generalized stress responses, as evident from the Western blot analysis of select hits in cells infected with two non-coronaviruses (Fig. 4b) .

In all, this study uncovers the phenomenon of SARS-CoV-2-mediated desensitization to IFN. These are critical findings that will enhance our understanding of how SARS-CoV-2 mutes the innate immune system to sustain its replication, leading to impaired adaptive immune responses and consequently severe disease. The knowledge gained from these studies will provide the foundation for the development of therapeutic interventions aimed at boosting cell-intrinsic antiviral responses and inform the design of attenuated viruses as potential vaccine candidates.

All cell lines were incubated at 37ºC and 5% CO2 in a humidified incubator. Human 

Expression plasmid encoding the spike protein of SARS-CoV-2, pCG1_SARS-2_S, has recently been described and was a kind gift from Stefan Pohlmann 42 . The plasmids pCAGGS_TMPRSS2-Flag and pcDNA3.1_ACE2, encoding human ACE2 and TMPRSS2, respectively, were obtained from Thomas Gallagher (Loyola University). We transferred ACE2 and untagged TMPRSS2 to the lentiviral pLOC vector to obtain pLOC_hACE2_PuroR and pLOC_hTMPRSS2_BlastR, respectively.

We used 2019-nCoV/USA-WA1/2020 isolate (NCBI accession number: MN985325) of SARS-CoV-2, obtained from the Centers for Disease Control and Prevention and BEI Resources.

To generate the passage 1 (P1) virus stock, we infected Vero E6 cells, seeded one day prior into a 175 cm 2 flask at a density of 10 million cells, with the master stock diluted in 10 ml of Opti-MEM.

Following virus adsorption to the cells at 37ºC for 1h, we added 15 ml of DMEM containing 10% FBS and 1X penicillin/streptomycin. The next day, we removed the inoculum, rinsed the cell monolayer with 1X PBS, and added 25 ml of fresh DMEM containing 2% FBS. Two days later, when the cytopathic effect of the virus was clearly visible, as evidenced by a large number of round floating cells, we collected the culture medium, passed it through a 0.2µ filter, and stored at -80ºC. We then prepared the P2 working stock of the virus by infecting Vero E6 cells with the P1 stock at a multiplicity of infection (MOI) of 0.1 plaque forming units (PFU)/cell and harvesting the culture medium three days later.

To determine the titer of our viral stock by plaque assay, we seeded Vero E6 cells into a 12-well plate at a density of 2.5 x 10 5 cells per well. The next day, the cells were infected with serial 10-fold dilutions of the virus stock for 1h at 37ºC. We then added 1 ml per well of the overlay medium containing 2X DMEM (Gibco; #12800017) supplemented with 4% FBS and mixed at a 1:1 ratio with 1.2% Avicel (DuPont; RC-581) to obtain the final concentrations of 2% and 0.6% for FBS and Avicel, respectively. Three days later, the overlay medium was removed, the cell monolayer was washed with 1X PBS and fixed for 30 minutes at room temperature with 4% paraformaldehyde. Fixed cells were then washed with 1X PBS and stained for 1h at room temperature with 0.1% crystal violet prepared in 10% ethanol/water. After rinsing with tap water, the number of plaques were counted and the virus titer was calculated. The titer of our P2 virus stock was 1 x 10 7 PFU/ml.

VSV pseudoparticles carrying the SARS-CoV-2 S protein were generated as previously described 42 . Briefly, 293T cells were seeded into a 6-well plate at the density of 5x10 5 cells per well. The next day, the cells were transfected with 6 µg of pCG1_SARS-2_S using X-tremeGENE 9 DNA transfection reagent (Sigma-Aldrich). Twenty hours later, the cells were inoculated with a replication-competent vesicular stomatitis virus (VSV) modified to contain an expression cassette for GFP in place of the VSV-G open reading frame, VSV*ΔG-GFP (kindly provided by Stefan Pohlmann of the Leibniz Institute for Primate Research (DPZ), Gottingen, Germany). Following 2h incubation of cells with VSV*ΔG-GFP at 37ºC, the inoculum was removed and the cells were washed three times with FBS-free DMEM. Two ml of DMEM/10%FBS supplemented with anti VSV-G antibody was then added to each well to neutralize any residual input VSV.

Pseudoparticles were harvested 20h later, passed through 0.45 µ filter, and stored at -80ºC.

For infection experiments, target cells grown in 24-well plates to the confluency of 70-80%

were infected with pseudoparticles. Twenty-four hours later, the cells, including those floating around in the culture medium due to cytopathic effects of VSV replication, were collected and fixed in 4% PFA. Flow cytometry was performed to count the percentage of GFP positive cells.

To measure the mRNA abundance of ISGs, total RNA was isolated from cells using Qiagen RNeasy Plus Mini Kit (Qiagen #74134), according to the manufacturer's instructions, with an additional on-column DNase treatment (Qiagen; #79256). RT-qPCR was performed using Luna® Universal One-Step RT-qPCR kit (New England Biolabs; #E3005L). Briefly, a 12 µl of reaction mixture containing 2 µl of RNA, 0.4 µM of each forward and reverse primer, 0.6 µl of the 20X Luna WarmStart® RT Enzyme Mix, and 6 µl of the 2X Luna Universal One-Step Reaction Mix was subjected to one-step RT-qPCR using Applied Biosystems QuantStudio 3 (ThermoFisher Scientific), with the following cycling conditions; reverse transcription at 50°C for 10 min, initial denaturation at 95°C for 2 min followed by 40 cycles of denaturation at 95°C for 15 sec and annealing/extension at 60°C for 1 min, ending with the melt curve analysis of the PCR product from 65ºC to 95ºC, rising in 0.5ºC per second increments, waiting for 30 sec at 65ºC and for 5 sec at each step thereafter, and acquiring fluorescence at each temperature increment. The Cq values were determined using the QuantStudio TM Design and Analysis software V1.5.1. RPS11 was used as a housekeeping gene and the ISG Cq values were normalized against this gene to calculate the fold change between untreated and IFN-treated cells.

Virus-infected cells were fixed in 4% paraformaldehyde for 30 minutes. The fixative was 

We infected cells grown to the confluency of 90-95% in 6-well plates with SARS-CoV-2 at an MOI of 1. To synchronize virus entry into cells, the infection was carried out in a small volume 

Dried samples were reconstituted in mobile phase A solvent (2% acetonitrile and 0.1% formic acid) for analysis on the Q-Exactive™ HF-X mass spectrometer (ThermoFisher Scientific), interfaced to the Easy nanoLC1200 HPLC system (ThermoFisher Scientific). The peptides were loaded on a reversed-phase nano-trap column in mobile phase A (75μm i.d. × 2 cm, Acclaim PepMap100 C18 3μm, 100Å; ThermoFisher Scientific; # 164946) and separated over an EASY-Spray column, (ThermoFisher Scientific; #ES803A) using a gradient (6% to 19% over 58 min, then 19% to 36% over 34 min) of mobile phase B (0.1% formic acid, 80% acetonitrile) at a flow rate of 250 nl/min. The mass spectrometer was operated in positive ion mode with a spray voltage of 2100 volts and the data was acquired in a data-dependent acquisition (DDA) mode. Precursor scans were acquired at a resolution of 120,000 FWHM with a maximum injection time of 120 ms.

The top 12 abundant ions, with charge states ≥2, were selected for fragmentation by HCD (collision energy 29%) and analyzed at a resolution of 45,000 FWHM with a maximum injection time of 250 ms.

All raw data were processed using MaxQuant (Version 1.6.7.0). The acquired tandem spectra were searched against the reference Homo sapiens proteome (Taxonomic ID: 9606) FASTA file downloaded from UniProt on April 2017, concatenated with common contaminants and SARS-CoV-2 proteome sequences. TMT reporter ion quantification was performed on MaxQuant using default settings. For searches, cysteine carbamido-methylation was specified as fixed modification and oxidation of methionine and N-terminal protein acetylation were set as variable modifications. Enzyme specificity was set to trypsin and up to two missed cleavages were allowed. The MaxQuant output file designated "ProteinGroups.txt" was used for data normalization and statistical analyses using in-house generated scripts in the R environment.

Bioinformatic analysis was performed using R: A language and environment for Statistical In the case of duplicate proteins mapping to a common gene symbol, the one with the highest absolute value rank was retained. 

To test interferon response in uninfected and SARS-CoV-2-infected cells, we seeded cells either in 6-well plates (for Western blot) at a density of 5 x 10 5 cells per well, in 12-well plates at a density of 2 x 10 5 cells per well (for RT-qPCR), or in 96-well plates at a density of 2.5 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Neuroinvasion of SARS-CoV-2 in human and mouse brain. bioRxiv

Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection. bioRxiv

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Addressing accuracy and precision issues in iTRAQ quantitation

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Cellular mRNA decay protein AUF1 negatively regulates enterovirus and human rhinovirus infections

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

The regulation of JAKs in cytokine signaling and its breakdown in disease

Janus kinases in immune cell signaling

The Jak-STAT pathway stimulated by interferon alpha or interferon beta

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

Janus kinase-signal transducer and activator of transcription mediates phosphatidic acid-induced interleukin (IL)-1beta and IL-6 production

Innate Control of Adaptive Immunity: Beyond the Three-Signal Paradigm

COVID-19: Loss of bridging between innate and adaptive immunity?

Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Cell entry mechanisms of SARS-CoV-2

Animal models for COVID-19

Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI)

Hepatic apo-A-I and apo-E and intestinal apo-A-I are synthesized in precursor isoprotein forms by organ cultures of human fetal tissues

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Proteomic and Metabolomic Characterization of COVID-19

limma powers differential expression analyses for RNA-sequencing and microarray studies

Enrichment map: a networkbased method for gene-set enrichment visualization and interpretation

Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap

All authors read and approved the manuscript.